Multihance (Gadobenate Dimeglumine)

Gadobenate dimeglumine, the active ingredient in Multihance, is a gadolinium‑based contrast agent presented as a 0.5 mmol/mL solution for injection for intravenous use. It is employed to improve magnetic resonance imaging quality of the liver, central nervous system, cardiovascular system, and abdomen/pelvis in adult patients undergoing diagnostic examinations.

GNH USA supplies Multihance as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, imaging centres, pharmacies and clinics worldwide. The company emphasizes quality assurance and regulatory compliance across EU and global markets.

Multihance is used as a gadolinium‑based contrast medium to enhance magnetic resonance imaging of various organ systems.

- Liver MRI: Improves detection and characterization of focal liver lesions by increasing T1 signal intensity. - Central nervous system MRI: Enhances visualization of brain and spinal cord structures, aiding in the assessment of tumors, vascular malformations, and inflammatory lesions. - Cardiovascular MRI: Provides clearer delineation of cardiac chambers, vessels, and myocardial perfusion, supporting evaluation of congenital and acquired heart disease. - Abdomen and pelvis MRI: Improves contrast between abdominal organs and pathological lesions, facilitating diagnosis of tumors, inflammatory conditions, and vascular abnormalities.

Adverse reactions to Multihance may range from mild, transient events to rare, serious conditions.

Common Side Effects: - Nausea: mild nausea occurring shortly after injection. - Injection site discomfort: pain or warmth at the infusion site. - Metallic taste: brief metallic sensation in the mouth.

Serious or Rare Side Effects: - Nephrogenic systemic fibrosis: fibrotic skin changes in patients with severe renal impairment. - Severe allergic reaction: anaphylaxis or angioedema requiring emergency treatment. - Hypotension: marked drop in blood pressure during or after administration.

When using Multihance, clinicians should observe several safety measures.

- Renal function assessment: evaluate kidney function before administration. - Pregnancy: use only if clearly needed, as safety has not been established. - Allergy history: screen for prior reactions to gadolinium agents. - Hydration: ensure adequate hydration to promote renal clearance. - Avoid in patients with severe renal impairment: consider alternative imaging techniques. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Multihance may interact with other agents or conditions that affect renal function or gadolinium exposure.

Major Interactions (Avoid): - Severe renal impairment: increased risk of nephrogenic systemic fibrosis; avoid use. - Concurrent use of other gadolinium agents: cumulative gadolinium load; avoid simultaneous administration.

Moderate Interactions (Monitor Closely): - Nephrotoxic drugs (e.g., aminoglycosides, NSAIDs): monitor renal function closely. - Diuretics: may affect hydration status; ensure adequate fluid balance. - Prophylactic steroids or antihistamines: may mask early signs of allergic reaction; monitor patient response.